FDA Brief

Warning letters Drugs

FDA warning letter to

Master Pharmaceuticals Group

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.

What happened

In August 2025, FDA reviewed the website https://www.master-pharmaceuticals.com and observed that it offered compounded semaglutide and tirzepatide drug products. FDA found website claims labeling the products “Semaglutide (Ozempic/Wegovy)” and “Tirzepatide (Mounjaro/Zepbound).” FDA said these claims imply the compounded products are the same as FDA-approved products when they are not, so the products are misbranded.

What FDA found

  1. Website claims compared compounded semaglutide and tirzepatide to FDA-approved brand products, making the labeling false or misleading.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. Advertising or promotion for the compounded drugs was false or misleading.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. Misbranded products were introduced or delivered for introduction into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. Receipt or delivery of misbranded drugs in interstate commerce is prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells the company to take immediate action, including ceasing the misleading language, and to respond in writing within 15 working days to OCQC in CDER describing corrective steps, how it will prevent recurrence, and related documents. If it cannot complete the matter in that time, it must explain the delay and give a timeframe.

Who should pay attention

  • telehealth companies selling compounded semaglutide or tirzepatide
  • compounding pharmacies and their marketing partners
  • brands or consumers buying compounded GLP-1 drugs online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk